AU2933997A - Therapies for chronic renal failure - Google Patents

Therapies for chronic renal failure

Info

Publication number
AU2933997A
AU2933997A AU29339/97A AU2933997A AU2933997A AU 2933997 A AU2933997 A AU 2933997A AU 29339/97 A AU29339/97 A AU 29339/97A AU 2933997 A AU2933997 A AU 2933997A AU 2933997 A AU2933997 A AU 2933997A
Authority
AU
Australia
Prior art keywords
renal failure
chronic renal
therapies
risk
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29339/97A
Other languages
English (en)
Inventor
Charles M. Cohen
Kuber T. Sampath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Biomolecules Inc
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Priority to AU29339/97A priority Critical patent/AU2933997A/en
Publication of AU2933997A publication Critical patent/AU2933997A/en
Priority to AU71419/00A priority patent/AU757969B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU29339/97A 1996-05-06 1997-05-06 Therapies for chronic renal failure Abandoned AU2933997A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU29339/97A AU2933997A (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure
AU71419/00A AU757969B2 (en) 1996-05-06 2000-11-03 Therapies for chronic renal failure

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
US08643321 1996-05-06
PCT/US1997/007655 WO1997041880A1 (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure
AU29339/97A AU2933997A (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU71419/00A Division AU757969B2 (en) 1996-05-06 2000-11-03 Therapies for chronic renal failure

Publications (1)

Publication Number Publication Date
AU2933997A true AU2933997A (en) 1997-11-26

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
AU29339/97A Abandoned AU2933997A (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure
AU28322/97A Abandoned AU2832297A (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU28322/97A Abandoned AU2832297A (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Country Status (11)

Country Link
US (5) US6498142B1 (enExample)
EP (2) EP0910400B1 (enExample)
JP (4) JP2000510835A (enExample)
AT (2) ATE277629T1 (enExample)
AU (2) AU2933997A (enExample)
CA (2) CA2254954C (enExample)
DE (2) DE69723845T2 (enExample)
DK (2) DK0910400T3 (enExample)
ES (2) ES2230604T3 (enExample)
PT (2) PT914146E (enExample)
WO (2) WO1997041881A1 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU743510B2 (en) 1997-05-05 2002-01-24 Stryker Corporation Therapies for acute renal failure
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
EP0896825B1 (en) 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
JP2002526034A (ja) * 1998-07-28 2002-08-20 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−１１
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
NZ517781A (en) * 1999-09-14 2004-01-30 Biogen Inc Therapies for chronic renal failure using one or more integrin antagonists
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006516020A (ja) * 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
US7576052B2 (en) 2003-10-17 2009-08-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
AU2005228696B2 (en) 2004-03-30 2010-06-24 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
EP3536704B1 (en) 2005-11-14 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Gene therapy for renal failure
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
WO2007087570A2 (en) 2006-01-24 2007-08-02 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
ES2379603T3 (es) 2006-05-30 2012-04-27 Antibodyshop A/S Métodos para la evaluación rápida de la gravedad de un traumatismo
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
WO2008010556A1 (fr) * 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
US20080255181A1 (en) * 2006-12-15 2008-10-16 University Of Heidelberg Methods for treating podocyte-related disorders
WO2008134297A2 (en) * 2007-04-24 2008-11-06 Johnson & Johnson Regenerative Therapeutics, Llc Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
JP2011523357A (ja) * 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
JP5485885B2 (ja) * 2008-06-24 2014-05-07 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
CN105067819B (zh) * 2008-08-28 2018-05-22 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN105021826A (zh) * 2008-08-29 2015-11-04 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
AU2009308497B2 (en) * 2008-10-21 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20110084286A (ko) 2008-11-10 2011-07-21 아스튜트 메디컬 인코포레이티드 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
CA2743253A1 (en) * 2008-11-22 2010-05-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104111336B (zh) * 2009-02-06 2017-01-18 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后
AU2010213575B2 (en) * 2009-02-12 2013-11-14 Stryker Corporation Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
EP2396026A2 (en) 2009-02-12 2011-12-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
WO2010103070A2 (en) 2009-03-12 2010-09-16 Charité - Universitätsmedizin Berlin Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US8871459B2 (en) 2009-08-07 2014-10-28 Astute Medical, Inc. Method for evaluating renal status by determining beta-2-glycoprotein 1
AU2010295509A1 (en) 2009-09-17 2012-04-19 Stryker Corporation Buffers for controlling the pH of bone morphogenetic proteins
US10324093B2 (en) 2009-11-07 2019-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ600828A (en) 2009-12-20 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
SI2666872T1 (sl) 2010-02-05 2016-08-31 Astute Medical, Inc. Postopki in sestavki za diagnozo in prognozo ledvične poškodbe in odpovedi ledvic
KR20140051754A (ko) 2010-02-26 2014-05-02 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
EP2576587B1 (en) 2010-05-24 2018-03-21 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
EP2585825B1 (en) 2010-06-23 2018-01-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR101800596B1 (ko) 2010-08-20 2017-11-22 와이어쓰 엘엘씨 디자이너 골형성 단백질
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
US10813946B2 (en) 2012-10-08 2020-10-27 Vifor (International) Ltd. Potassium binding polymers for treating hypertension and hyperkalemia
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP4105657B1 (en) 2013-01-17 2024-09-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP3069149B1 (en) * 2013-11-11 2022-05-18 General Electric Company Method for reducing error in rotor speed measurements
EP2944326B1 (en) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN109803977B (zh) 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
CA2030518C (en) 1989-03-28 2000-03-21 Elizabeth A. Wang Osteoinductive compositions
DK0536186T3 (da) 1990-05-16 2002-05-21 Genetics Inst Knogle- og brusk-dannelsesfremkaldende proteiner
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
JPH05509086A (ja) * 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ES2149776T5 (es) 1991-08-30 2004-07-01 Curis, Inc. Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
CA2116560C (en) 1991-08-30 2002-01-08 Charles M. Cohen Morphogenic protein screening method
EP1637156A1 (en) 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
JPH07509720A (ja) 1992-07-31 1995-10-26 クリエイティブ　バイオモレキュルズ，インコーポレイテッド モルフォゲン強化栄養組成物
KR950702627A (ko) 1992-07-31 1995-07-29 찰스 엠. 코헨 모르포겐 단백질의 가용성 복합체 및 그의 조성물(Morphogenic Protein Soluble Complex and Composition Thereof)
EP0653942B2 (en) 1992-07-31 2007-03-07 Curis, Inc. Morphogen-induced nerve regeneration and repair
DK0661987T3 (da) 1992-09-16 1998-09-14 Creative Biomolecules Inc Morphogeninduceret leverregeneration
AU681362B2 (en) 1992-11-03 1997-08-28 Stryker Corporation OP-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
DE69434914T2 (de) 1993-03-04 2007-10-31 Stryker Corp., Kalamazoo Verfahren und zusammensetzungen zur herstellung von rekombinantem osteogenischem protein
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
ATE225666T1 (de) * 1993-11-15 2002-10-15 Celtrix Pharma Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE69723429T3 (de) * 1996-03-22 2007-09-20 Curis, Inc., Cambridge Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
CA2254954C (en) 2010-01-12
US20100291170A1 (en) 2010-11-18
EP0914146A1 (en) 1999-05-12
WO1997041881A1 (en) 1997-11-13
US20050143304A1 (en) 2005-06-30
DK0910400T3 (da) 2003-11-24
EP0910400B1 (en) 2003-07-30
US8017580B2 (en) 2011-09-13
PT910400E (pt) 2003-12-31
CA2254954A1 (en) 1997-11-13
EP0914146B1 (en) 2004-09-29
DE69730966D1 (de) 2004-11-04
JP4766722B2 (ja) 2011-09-07
ATE277629T1 (de) 2004-10-15
DE69730966T2 (de) 2006-02-23
US7524817B2 (en) 2009-04-28
JP2000510835A (ja) 2000-08-22
CA2254953A1 (en) 1997-11-13
JP2000510124A (ja) 2000-08-08
ES2203803T3 (es) 2004-04-16
DE69723845D1 (de) 2003-09-04
US6498142B1 (en) 2002-12-24
DK0914146T3 (da) 2005-01-31
JP2012229268A (ja) 2012-11-22
US6861404B1 (en) 2005-03-01
CA2254953C (en) 2006-09-26
ATE245997T1 (de) 2003-08-15
EP0910400A1 (en) 1999-04-28
PT914146E (pt) 2005-02-28
JP5247593B2 (ja) 2013-07-24
JP2009185076A (ja) 2009-08-20
US20120004171A1 (en) 2012-01-05
US8377878B2 (en) 2013-02-19
ES2230604T3 (es) 2005-05-01
AU2832297A (en) 1997-11-26
DE69723845T2 (de) 2004-06-03
WO1997041880A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
AU2933997A (en) Therapies for chronic renal failure
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
AU6889896A (en) Syringe serving also as an ampule and syringe for collecting blood
EP0212474A3 (en) Bone morphogenetic peptides
DE69432582D1 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
NO970536D0 (no) Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate
MXPA03011386A (es) Proteina de union para su uso en la regeneracion de hueso o cartilago.
AU3866097A (en) Naphtholactams and lactones as bone morphogenetic protein active agents
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
WO2000020449A3 (en) MODIFIED TGF-β SUPERFAMILY PROTEINS
NO982436D0 (no) Apparat for oppvarming av blod
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
EP0766974A3 (en) Blood reservoir, blood delivery instrument, and blood delivery apparatus
DK0980252T3 (da) Terapier til akut nyresvigt
AU3909497A (en) Anti-chlamydial methods and materials
WO2004019876A3 (en) Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
AU2242897A (en) Protein occlusion for delivery of small molecules
BR9713514A (pt) Novo uso de creatina
ZA966577B (en) Pharmaceutical composition.
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
ATE222479T1 (de) Einheit zur knorpelreparatur
ATE206930T1 (de) Verwendung von osteoblast-proliferationsfaktor
FR2729074B1 (fr) Ecrou taraude autofreinant pour l'assemblage d'appareillages de chirurgie reconstructive, notamment en osteosynthese rachidienne

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted